| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32be27728eda26cdbc0ac0e689726b0e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 |
| filingDate |
2016-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c142faf8adb5c80c899eb87327983637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6502653a8c3791b0acbe8e0c5e76afb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbbba194a07ba545e69271a87dceb8fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bd37900cf465d14157f5420f9bd8fea |
| publicationDate |
2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017113489-A1 |
| titleOfInvention |
Ingenol compounds and use thereof in anti-hiv latency treatment |
| abstract |
Provided in the present invention are ingenol compounds and a use thereof in preparing an anti-HIV latency drug. In particular, provided in the present invention is a use of ingenol compounds and pharmaceutically acceptable salts thereof for preparing a drug for: (a) intervening with HIV viral latency; (b) activating an HIV virus that has been integrated into mammalian genomes; and/or (c) inducing the expression of the dormant HIV provirus in infected cells. The compounds of the present invention may also be used in combination with antiretroviral drugs to accelerate the removal of latent viral reservoirs. |
| priorityDate |
2015-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |